Recombinant protein · Protein replacement · developed by Biomarin Pharm
Elosulfase alfa is a recombinant form of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase, which is taken up into lysosomes via mannose-6-phosphate receptors and increases the breakdown of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate. It is used in mucopolysaccharidosis type IVA (Morquio A syndrome), a lysosomal storage disorder caused by deficiency of this enzyme.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Oct 30, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03204370 | N/A | Mucopolysaccharidosis IV A | Completed | BMRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mucopolysaccharidosis IV A
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.
See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMRN catalysts and pipeline →